Skip to main content
Premium Trial:

Request an Annual Quote

Friedrich von Bohlen, Martin Hollenhorst, Daniel Keesman, Lee Bendekgey, Patricia Schreck, John Keller, Charles Cantor, and Mikhail Gishizky


Friedrich von Bohlen, CEO of Lion Bioscience, announced last week that he plans to resign as of Dec. 31. CFO Martin Hollenhorst and Daniel Keesman, chief business officer, will split the company’s leadership duties beginning Jan. 1. Von Bohlen said he plans to join the company’s supervisory board. (See page 9 for an interview with von Bohlen regarding his decision to step down).

Lee Bendekgey, who has served as Incyte’s general counsel since 1998 and recently as general manager of the company’s information products group, will be leaving the company to “pursue other interests,” the company said last week. Incyte has appointed Patricia Schreck to replace Bendekgey as executive vice president and general counsel. Schreck joins the company from Elan Drug Delivery, where she was chief patent counsel. John Keller, Incyte’s executive vice president and chief business officer, will serve as general manager of the information products group.

Charles Cantor has joined the scientific advisory board of GeneGo, the company said last week. Cantor is currently CSO and a board director of Sequenom and director of the Center for Advanced Biotechnology at Boston University.

Entelos has appointed Mikhail Gishizky as CSO. He joins the company from SUGEN/Pharmacia, where he served as vice president of target discovery.

Filed under